Inventors: Farhad Imani, M.D., David
Key words: therapeutic, immune, anti-inflammatory, autoimmune, vaccine, multiple sclerosis
Brief Description: The literature shows an association between anti-viral vaccination and onset of childhood asthma. We have noted that attenuation of viral target by conventional vaccine preparation does not completely remove or degrade viral nucleic acids such as double-stranded RNA (dsRNA). It is known that viral dsRNA can induce activation of a hostís anti viral protein kinase (PKR). We have shown that activation of PKR by dsRNA leads to expression of Th2-type immune responses, e.g. allergy and asthma. Our invention exploits this newly identified correlation and offers a simple and inexpensive solution to the problem of vaccine-induced childhood asthma or allergy. Ultraviolet and ionizing radiation is known to cause degradation of viral nucleic acid. Therefore, irradiation of antiviral vaccine preparations will degrade viral dsRNA, preventing dsRNA-activation of PKR and its resultant pathological Th2-type immune response.
Patent Status: U.S. provisional application filed
Potential Commercial Use: This invention provides irradiated antiviral preparations, and the use of these preparations to allow for effective vaccination with decreased risk of induction or exacerbation of asthma or allergic sensitivity. The point of novelty in this invention is a very low cost process step in vaccine preparation that does not require exotic or high technology equipment.
Contact: Heather Bakalyar, Ph.D.
The Johns Hopkins University School of Medicine
Office of Technology Licensing
111 Market Place, Suite 906
Baltimore, Maryland 21202
(410) 347-3205: telephone
(410) 347-3201: facsimile